Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arete Therapeutics Inc.

Latest From Arete Therapeutics Inc.

Galleon ships in Merck figureheads

Galleon Pharmaceuticals has appointed Dr Euan MacIntyre senior vice-president of drug discovery, and Dr James McLeod senior vice-president of clinical research & development and chief medical officer. Dr MacIntyre was previously senior vice-president and head of drug discovery at Arete Therapeutics and vice-president of basic research-pharmacology at Merck & Co. Dr McLeod previously managed the experimental medicine group at Merck Research Laboratories.

Genentech's New Deal Maker

In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.

BioPharmaceutical Business Strategies

Start-Up Previews (03/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.

Arete Therapeutics Inc.

Arete Therapeutics launched in 2003 with a straightforward therapeutic and commercial goal: to develop a new treatment for high blood pressure that works by blocking the s-EH enzyme. Arete began enrolling patients for its first human trial in November 2007, and its oral inhibitor of s-EH proved safe. By the time the safety data were released a year later, Arete's strategy had been further refined and the company was envisioning the compound as a potential therapy for metabolic syndrome. Based on data from preclinical studies, Arete now posits that its therapy can become a treatment for type 2 diabetes.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gynecological, Urological
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arete Therapeutics Inc.
  • Senior Management
  • Contact Info
  • Arete Therapeutics Inc.
    Phone: (510) 785-7060
    3912 Trust Way
    Hayward, CA 94545